对温琴察·孔泰杜卡、乔吉娅·古廖利和乌戈·德·乔治致编辑的信的回复，信的主题为：尼文·梅赫拉、大卫·多林、塞米尼·苏马纳苏里亚等人。两项III期试验（FIRSTANA和PROSELICA）中转移性去势抵抗性前列腺癌患者血浆游离DNA浓度与紫杉烷治疗结果。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2018.02.013 。 - Suppr

Suppr

超能文献

Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.

作者信息

Mehra Niven, Dolling David, de Bono Johann

机构信息

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.

出版信息

Eur Urol. 2018 Sep;74(3):e69-e70. doi: 10.1016/j.eururo.2018.05.016. Epub 2018 Jun 1.

DOI:10.1016/j.eururo.2018.05.016

PMID:29866468

Abstract

摘要

相似文献

Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.对温琴察·孔泰杜卡、乔吉娅·古廖利和乌戈·德·乔治致编辑的信的回复，信的主题为：尼文·梅赫拉、大卫·多林、塞米尼·苏马纳苏里亚等人。两项III期试验（FIRSTANA和PROSELICA）中转移性去势抵抗性前列腺癌患者血浆游离DNA浓度与紫杉烷治疗结果。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2018.02.013 。

Eur Urol. 2018 Sep;74(3):e69-e70. doi: 10.1016/j.eururo.2018.05.016. Epub 2018 Jun 1.

Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:283-91.回复：尼文·梅赫拉、大卫·多林、塞米尼·苏马纳苏里亚等人。两项III期试验（FIRSTANA和PROSELICA）中转移性去势抵抗性前列腺癌患者血浆游离DNA浓度与紫杉烷治疗结果。《欧洲泌尿外科杂志》2018年；74卷：283 - 291页。

Eur Urol. 2018 Sep;74(3):e67-e68. doi: 10.1016/j.eururo.2018.05.015. Epub 2018 May 24.

Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.对温琴扎·孔泰杜卡、克里斯蒂安·洛利和乌戈·德·乔治给编辑的信的回复，信的主题为：帕斯夸莱·雷西格诺、大卫·洛伦特、迪莱塔·比安基尼等人的《醋酸阿比特龙治疗4周后前列腺特异性抗原下降与转移性去势抵抗性前列腺癌患者的总生存期》。《欧洲泌尿外科杂志》2016年；70卷：724 - 31页

Eur Urol. 2016 Dec;70(6):e170-e171. doi: 10.1016/j.eururo.2016.05.029. Epub 2016 May 27.

Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.对罗伯特·J·范·索斯特和罗纳德·德·威特致编辑的信的回复，信的主题为：约翰·S·德博诺、马修·R·史密斯、弗雷德·萨德等人。醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU - AA - 302的事后分析。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.06.033 。

Eur Urol. 2017 Jan;71(1):e11. doi: 10.1016/j.eururo.2016.10.005. Epub 2016 Oct 14.

Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.对吉安多梅尼科·罗维耶洛、达尼埃莱·热纳拉利和罗伯托·彼得廖利致编辑的信的回复，信的主题为：约翰·S·德博诺、马修·R·史密斯、弗雷德·萨德等人。醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU - AA - 302的事后分析。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.06.033 。

Eur Urol. 2017 Feb;71(2):e56. doi: 10.1016/j.eururo.2016.08.011. Epub 2016 Aug 17.

Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.对伊桑·B·卢德米尔、扎卡里·R·麦考和李-珍·魏致编辑信的回复：关于卡里姆·菲扎齐、查尔斯·G·德雷克、托马什·M·比尔等人的研究。多西他赛后转移性去势抵抗性前列腺癌放疗后伊匹木单抗与安慰剂对比的III期试验最终分析确定了长期存活者过多。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.07.032。解读放疗后伊匹木单抗对多西他赛后转移性去势抵抗性前列腺癌患者的疗效。

Eur Urol. 2021 Jan;79(1):e12-e13. doi: 10.1016/j.eururo.2020.10.012. Epub 2020 Oct 26.

Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.回复冯琦、徐子成和邹清致编辑的信，信的内容关于：安德里亚·勒尔、阿里夫·侯赛因、阿卡什·帕奈克等人。鲁卡帕尼治疗后转移性去势抵抗性前列腺癌患者中BRCA回复突变的出现。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.09.010 。

Eur Urol. 2023 Mar;83(3):e78. doi: 10.1016/j.eururo.2022.12.023. Epub 2023 Jan 7.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.回复乌戈·德·乔治、温琴扎·孔泰杜卡和埃玛努埃拉·斯卡尔皮致编辑的信：关于马尔齐亚·德尔雷、伊丽莎·比亚斯科、斯特凡尼亚·克鲁奇塔等人的研究“血浆来源外泌体RNA中雄激素受体剪接变体7的检测强烈预测转移性前列腺癌患者对激素治疗的耐药性”。《欧洲泌尿外科杂志》2017年；71卷：680 - 7页

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9.

Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.回复约翰·S·德博诺、玛哈·侯赛因和金宇康致编辑的信：关于康拉德·H·斯托普萨克。PARP抑制在转移性去势抵抗性前列腺癌中的疗效与非BRCA DNA修复改变差异很大：从奥拉帕利3期PROfound试验中重建队列B的预设终点。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.09.024

Eur Urol. 2021 Mar;79(3):e81-e82. doi: 10.1016/j.eururo.2020.12.018. Epub 2020 Dec 23.

Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.对吉安多梅尼科·罗维耶洛、阿尔贝托·博蒂尼和达尼埃莱·热纳利致编辑的信的回复，信的主题为：卡里姆·菲扎齐、金恩智、约翰·S·德博诺等人。长期给转移性去势抵抗性前列腺癌患者服用低剂量泼尼松龙联合醋酸阿比特龙时，皮质类固醇相关不良事件的发生率较低。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.02.035。老年患者中的皮质类固醇相关不良事件。

Eur Urol. 2016 Aug;70(2):e42. doi: 10.1016/j.eururo.2016.05.005. Epub 2016 May 18.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验